AU2021203786B2 — Deuterated derivatives of ivacaftor
Assigned to Vertex Pharmaceuticals Europe Ltd · Expires 2023-03-16 · 3y expired
What this patent protects
C:\Interwo n\NRPortbl\DCC\BAS\19236078_I.docx-8/28/2019 ABSTRACT This invention relates to compounds of Formula I: OH Y1 X1 O O / Y3 N X H X3# N X 5 Y4 Y 6 X4 H Formula I and pharmaceutically acceptable salts thereof. This invention also provides compositions comprisin…
USPTO Abstract
C:\Interwo n\NRPortbl\DCC\BAS\19236078_I.docx-8/28/2019 ABSTRACT This invention relates to compounds of Formula I: OH Y1 X1 O O / Y3 N X H X3# N X 5 Y4 Y 6 X4 H Formula I and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.